Core Insights - The Horizon Kinetics Medical ETF (MEDX) has reached a 52-week high, increasing by 49.9% from its low of $23.46 per share [1][5] - The ETF focuses on patented first-line pharmaceuticals and biologics, with an annual fee of 85 basis points [2][5] - The rise in MEDX's value is attributed to strong performance in the healthcare sector, particularly in specialized pharmaceuticals and biotech, with significant contributions from Eli Lilly in the GLP-1 market [3][5] - A positive weighted alpha of 28.43 indicates potential for further gains in the near term [4][5]